ReviewEuropean respiratory review : an official journal of the European Respiratory Society2023
How inhaled corticosteroids target inflammation in COPD.
Review in European respiratory review : an official journal of the European Respiratory Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Protective effects of resveratrol in animal models of chronic obstructive pulmonary disease: a preclinical systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Global research landscape and emerging trends of respiratory microbiota and asthma: a bibliometric analysis.Frontiers in cellular and infection microbiology · 2026Pooled it
- Changes in Retinal Nerve Fiber Layer Thickness in Patients With Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.The clinical respiratory journal · 2025Pooled it
- Extracellular vesicles from bronchoalveolar lavage fluid provide insights into the inhaled corticosteroids treatment response in COPD.Respiratory research · 2025Trial
- Myrtenol inhalation ameliorates lung injury induced by cigarette smoke in rats: the role of inflammation and oxidative stress.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Resveratrol Inhibits Macrophage Glucose Metabolism Reprogramming and Inflammatory Activation to Delay COPD Progression Through the TLR4/HK2 Pathway.Journal of cellular physiology · 2026Article
- Comparative Real-World Effectiveness of Fixed-Dose Triple Therapy Regimens in COPD: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Effects of Fine Particulate Matter on Systemic Inflammatory Biomarkers in Elderly Patients with Chronic Obstructive Pulmonary Disease Versus the Healthy Elderly: A Pilot Study.International journal of molecular sciences · 2026Article
- Corticosteroids in asthma and COPD: an inflammopharmacological perspective on molecular and genetic determinants.Molecular biology reports · 2026Review
- Association between inhaled corticosteroids and anti-PD-1/PD-L1 efficacy in patients with NSCLC with concurrent COPD.iScience · 2026Article
- Metabolic effects following initiation of single-inhaler triple therapy in COPD: a prospective observational study.Molecular medicine (Cambridge, Mass.) · 2026Observational
- Undiagnosed Coronary Artery Disease in Patients with COPD.Journal of clinical medicine · 2026Article
- Clinical classification of chronic obstructive pulmonary disease with invasive pulmonary aspergillosis: a retrospective study.Journal of thoracic disease · 2026Article
- Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities.Nature reviews. Drug discovery · 2026Review
- Impact of concurrent systemic and inhaled corticosteroid use on clinical outcomes in advanced lung cancer patients receiving immune checkpoint inhibitors.Respiratory research · 2026Article
- Effect of Exposure to Inhaled Corticosteroids on Lung Cancer Incidence - A Comparison of Earlier Study Methodology on the Financial Database of the Hungarian National Health Insurance Fund.International journal of chronic obstructive pulmonary disease · 2026Article
- Trans-cuff budesonide delivery and its effects on endotracheal intubation-induced subglottic injury.Frontiers in pediatrics · 2026Article
- Dual role of IL-17A in COPD: amplifier of inflammatory cascades and mediator of airway remodeling and alveolar destruction.Frontiers in immunology · 2026Review
- New approaches to treating chronic obstructive pulmonary disease with Colla corii asini.Animal models and experimental medicine · 2026Review
- The Role of Advanced Lung Cancer Inflammation Index in Predicting COPD Exacerbation Risks.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled corticosteroids (ICS) are the most commonly used anti-inflammatory drugs for the treatment of COPD. COPD has been previously described as a "corticosteroid-resistant" condition, but current clinical trial evidence shows that selected COPD patients, namely those with increased exacerbation risk plus higher blood eosinophil count (BEC), can benefit from ICS treatment. This review describes the components of inflammation modulated by ICS in COPD and the reasons for the variation in response to ICS between individuals. There are corticosteroid-insensitive inflammatory pathways in COPD, such as bacteria-induced macrophage interleukin-8 production and resultant neutrophil recruitment, but also corticosteroid-sensitive pathways including the reduction of type 2 markers and mast cell numbers. The review also describes the mechanisms whereby ICS can skew the lung microbiome, with reduced diversity and increased relative abundance, towards an excess of proteobacteria. BEC is a biomarker used to enable the selective use of ICS in COPD, but the clinical outcome in an individual is decided by a complex interacting network involving the microbiome and airway inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.